Induction chemotherapy with gemcitabine and cisplatin in paranasal sinus tumours.

R. Hussain,A. Jamshed,M. Bilal,K. Shehzad,R. Azhar,M. A. Shah,S. Hameed,M. Arif,Z. Faruqui
DOI: https://doi.org/10.1200/jco.2006.24.18_suppl.15542
IF: 45.3
2006-06-20
Journal of Clinical Oncology
Abstract:15542 Background: There is no standard treatment for locally advanced carcinoma of paranasal sinuses. Induction chemotherapy is frequently used to down stage the disease. Surgery, radiotherapy and chemoradiation are all in use to treat the primary following neoadjuvant chemotherapy treatment. Cisplatin and gemcitabine are active agents in head and neck cancers. We evaluated the response of induction chemotherapy with cisplatin and gemcitabine in carcinoma of the paranasal sinuses. METHODS Between August 2005-November 2005, 5 patients with locally advanced carcinoma paranasal sinuses received induction chemotherapy at Shaukat Khanum Cancer Hospital and Research Centre. There were three males and two females, 19 to 65 (median 45) years of age. Three patients had maxillary and 2 patients had ethmoid sinus tumors. Four patients had Stage IVa and 1 patient had Stage IVb disease. All patients had biopsy proven carcinoma. Histologically the tumour was adenocarcinoma in 1 patient and squamous cell carcinoma in 4 patients. Four patients received 2 cycles and 1 patient received 1 cycle of cisplatin 75 mg/m2 day 1 and gemcitabine 1000 mg/m2 day 1 and 8 (repeat day 22) before radical treatment. Response was assessed in all patients with pre and post induction chemotherapy with CT or MRI scan. RESULTS Overall response rate was 60%. Complete response was seen in one patient and over 50% tumor regression in 2 patients. Disease remained unchanged (no response) in 1 patient. One patient progressed following one cycle and did not receive the second cycle of chemotherapy treatment. The treatment was well tolerated and no grade III or IV toxicity was seen. CONCLUSIONS The combination of gemcitabine and cisplatin in this schedule has low toxicity and significant activity in patients with locally advanced paranasal sinus tumors and is worthy of further study. No significant financial relationships to disclose.
What problem does this paper attempt to address?